Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6696-6700

  Song, Ivy ^a   Borland, Julie ^a   Chen, Shuguang ^a   Peppercorn, Amanda ^a   Wajima, Toshihiro ^b   Piscitelli, Stephen C ^a  

^a GLAXOSMITHKLINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; DOLUTEGRAVIR; FOSAMPRENAVIR PLUS RITONAVIR; CARBAMIC ACID DERIVATIVE; FOSAMPRENAVIR; FUSED HETEROCYCLIC RINGS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE; INTEGRASE INHIBITOR; ORGANOPHOSPHATE; RITONAVIR; SULFONAMIDE;

ABNORMAL DREAMING; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; NAUSEA; NORMAL HUMAN; PARESTHESIA; RASH; RISK ASSESSMENT; ADULT; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG INTERACTION;

ADULT; AREA UNDER CURVE; CARBAMATES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HEALTHY VOLUNTEERS; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; MALE; ORGANOPHOSPHATES; RITONAVIR; SULFONAMIDES;

EID: 84908568501     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03282-14     Document Type: Article

References (22)

1. Arribas JR, Eron J. 2013. Advances in antiretroviral therapy. Curr. Opin. HIV AIDS 8:341-349. http://dx.doi.org/10.1097/COH.0b013e328361fabd.
2. Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fujiwara T. 2012. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J. Acquir. Immune Defic. Syndr. 61:297-301. http://dx.doi.org/10.1097/QAI.0b013e31826bfd02.
3. Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, Piscitelli SC. 2010. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 54:254-258. http://dx.doi.org/10.1128/AAC.00842-09.
4. Song I, Borland J, Lou Y, Chen S, Patel P, Guta P, Wajima T, Peppercorn A, Piscitelli S. 2011. Effects of enzyme inducers, tipranavir and efavirenz, on the pharmacokinetics of the integrase inhibitor, dolutegravir (S/GSK1349572), abstr O-04. Abstr. 12th Int. Workshop Clin. Pharmacol. HIV Ther., Miami, FL.
5. Song I, Min SS, Borland J, Lou Y, Chen S, Patel P, Ishibashi T, Piscitelli SC. 2011. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J. Clin. Pharmacol. 51:237-242. http://dx.doi.org/10.1177/0091270010371113.
6. Song I, Borland J, Chen S, Lou Y, Peppercorn A, Wajima T, Min S, Piscitelli SC. 2011. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br. J. Clin. Pharmacol. 72:103-108. http://dx.doi.org/10.1111/j.1365-2125.2011.03947.x.
7. Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW. 2013. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab. Dispos. 41:353-361. http://dx.doi.org/10.1124/dmd.112.048918.
8. Castellino S, Moss L, Wagner D, Borland J, Song I, Chen S, Lou Y, Min SS, Goljer I, Culp A, Piscitelli SC, Savina PM. 2013. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor, dolutegravir, in humans. Antimicrob. Agents Chemother. 57:3536-3546. http://dx.doi.org/10.1128/AAC.00292-13.
9. Foisy MM, Yakiwchuk EM, Hughes CA. 2008. Induction effects of ritonavir: implications for drug interactions. Ann. Pharmacother. 42: 1048-1059. http://dx.doi.org/10.1345/aph.1K615.
10. Brüggemann RJ, van Luin M, Colbers EP, van den Dungen MW, Pharo C, Schouwenberg BJ, Burger DM. 2010. Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. J. Antimicrob. Chemother. 65:2188-2194. http://dx.doi.org/10.1093/jac/dkq280.
11. Luber A, Slowinski D, Acosta E, Pakes G, Pappa K, Condoluci D. 2009. Steady-state pharmacokinetics (PK) of fosamprenavir (FPV) and raltegravir (RAL) alone and combined with unboosted and ritonavir-boosted FPV, abstr A1-1297. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
12. Song I, Chen S, Piscitelli S, Min S. 2003. Pharmacokinetics (PK) and PK-pharmacodynamic (PD) relationship of dolutegravir (DTG) in integrase inhibitor (INI)-naive subjects, abstr A-1573. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother., Denver, CO.
13. European Medicines Agency (EMA). 2012. Guideline on the investigation of drug interactions. CPMP/EWP/560/95/Rev. 1. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/07/WC500129606 .pdf. Accessed 7 August 2014.
14. Patel P, Song I, Borland J, Patel A, Lou Y, Chen S, Wajima T, Peppercorn A, Min SS, Piscitelli SC. 2011. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-Administered with acid-reducing agents and multivitamins in healthy volunteers. J. Antimicrob. Chemother. 66:1567-1572. http://dx.doi.org/10.1093/jac/dkr139.
15. SAS Institute Inc. 2002. The NLP procedure, 2005, SAS OnlineDoc 9.1.3, SAS Institute Inc., Cary, NC. http://support.sas.com/onlinedoc/913/. Accessed 7 May 2014.
16. Ford SL, Chen Y-C, Lou Y, Borland J, Min SS, Yuen GJ, Shelton MJ. 2008. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Antimicrob. Agents Chemother. 52:534-538. http://dx.doi.org/10.1128/AAC.00724-07.
17. Wire MB, Ballow CH, Borland J, Shelton MJ, Lou Y, Yuen G, Lin J, Lewis EW. 2007. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged. Antimicrob. Agents Chemother. 51:2982-2984. http://dx.doi.org/10.1128/AAC.00008-07.
18. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S, SAILING Study Team. 2013. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferioritySAILINGstudy. Lancet 382:700-708. http://dx.doi.org/10.1016/S0140-6736(13)61221-0.
19. Nichols G, Mills A, Grossberg R, Lazzarin A, Maggiolo F, Molina J-M, Pialoux G, Wright D, Ait-Khaled M, Huang J, Vavro C, Wynne B, Yeo J. 2012. Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3. J. Int. AIDS Soc. 15(Suppl 4):18112.
20. ViiV Healthcare. 2013. Lexiva product information. ViiV Healthcare, Research Triangle Park, NC.
21. ViiV Healthcare. 2013. Tivicay summary of product characteristics (EU). ViiV Healthcare, Research Triangle Park, NC.
22. ViiV Healthcare. 2013. Tivicay prescribing information (US). ViiV Healthcare, Research Triangle Park, NC.